Longeveron (LGVN) Cash from Operations (2020 - 2026)
Longeveron (LGVN) recorded quarterly Cash from Operations of 4370000.0 in Q1 2026, up 17.48% quarter-over-quarter from 5296000.0 in Q4 2025, and up 6.96% on a YoY basis from 4085567.28 in Q1 2025.
Longeveron (LGVN) Cash from Operations (2020 - 2026) Analysis & Trends
Longeveron's Cash from Operations history runs 7 years deep, the most recent figure standing at 4370000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 6.96% year-over-year to 4370000.0; the TTM figure through Mar 2026 stood at 18318000.0 (down 18.34% YoY), while the FY2025 annual figure was 18645000.0, down 34.45% from the prior year.
- Cash from Operations was 4370000.0 for Q1 2026 at Longeveron, up from 5296000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2308000.0 in Q4 2022 to a low of 5848000.0 in Q1 2023.
- Historically, Cash from Operations has averaged 4109058.82 across 5 years, with a median of 4234000.0 in 2022.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 80.17% in 2022, then soared 47.23% in 2024.
- A 5-year view of Cash from Operations shows it stood at 2308000.0 in 2022, then tumbled by 73.18% to 3997000.0 in 2023, then advanced by 15.61% to 3373000.0 in 2024, then tumbled by 57.01% to 5296000.0 in 2025, then rose by 17.48% to 4370000.0 in 2026.
- The last three Cash from Operations figures came in at 4370000.0 (Q1 2026), 5296000.0 (Q4 2025), and 5055000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -4.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.37 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Mar 31, 2025 | -4.70 Mn |
| Mar 31, 2025 | -4.70 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -2.84 Mn |
| Sep 30, 2024 | -2.84 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | -4.00 Mn |
| Dec 31, 2023 | -4.00 Mn |